Petr Sedlacek
Overview
Explore the profile of Petr Sedlacek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
2489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millot F, Ampatzidou M, Roy Moulik N, Tewari S, Elhaddad A, Hammad M, et al.
Leukemia
. 2025 Mar;
PMID: 40044960
The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs)....
2.
Kowaluk A, Siewierska K, Choniawkova M, Sedlacek P, Kalwak K, Malicka I
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39913181
[...].
3.
Ince E, Galimard J, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, et al.
Haematologica
. 2024 Nov;
PMID: 39605204
Not available.
4.
Kalwak K, Moser L, Potschger U, Bader P, Kleinschmidt K, Meisel R, et al.
Blood Adv
. 2024 Nov;
9(4):741-751.
PMID: 39602342
The superiority of total body irradiation (TBI)-based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international,...
5.
Kalwak K, Vora A, Bader P, Burkhardt B, Corbacioglu S, Drabko K, et al.
Br J Clin Pharmacol
. 2024 Nov;
91(3):882-893.
PMID: 39563212
Aims: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a vital treatment for various paediatric malignant and nonmalignant diseases. The conditioning treatment before allo-HSCT is crucial for successful engraftment. Treosulfan, a...
6.
Klocperk A, riha P, Formankova R, Kyncl M, Sediva A, Sedlacek P
Pediatr Allergy Immunol
. 2024 Sep;
35(9):e14247.
PMID: 39291507
No abstract available.
7.
Tsilifis C, Speckmann C, Lum S, Fox T, Soler A, Mozo Y, et al.
J Allergy Clin Immunol
. 2024 Sep;
154(6):1534-1544.
PMID: 39218359
Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) insufficiency causes a primary immune regulatory disorder characterized by lymphoproliferation, dysgammaglobulinemia, and multiorgan autoimmunity including cytopenias and colitis. Objective: We examined the outcome of...
8.
Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, et al.
Br J Haematol
. 2024 May;
205(1):268-279.
PMID: 38803040
This prospective multicentre trial evaluated the safety and the efficacy of a thiotepa/melphalan-based reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) in children and adolescents with chronic myeloid leukaemia...
9.
Oostenbrink L, von Asmuth E, Jol-van der Zijde C, Jansen-Hoogendijk A, Vervat C, Bredius R, et al.
Haematologica
. 2024 May;
109(9):2854-2863.
PMID: 38721739
Anti-T-lymphocyte globulin (ATLG) is used in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure. To date, insight in ATLG pharmacokinetics and -dynamics (PK/PD) is limited,...
10.
Wachowiak J, Galimard J, Dalissier A, Rihani R, AlSaedi H, Wynn R, et al.
Bone Marrow Transplant
. 2024 Apr;
59(8):1057-1069.
PMID: 38627449
This retrospective study evaluated 35 children (median age 5.2 years; range 0.4-18) with myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary myelofibrosis transplanted from matched sibling donor...